Biotech News
UPDATE - Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical...
Open original release
Related news
SPROSpero Therapeutics2024-02-26 08:05 EST
Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference
SPROSpero Therapeutics2023-09-20 16:05 EST
Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference
ANTXAN2 Therapeutics2026-05-21 11:00 EST
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
ASMBAssembly Biosciences2026-05-11 12:00 EST
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
ANTXAN2 Therapeutics2026-02-17 12:00 EST
AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference
ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
OGENOragenics2026-05-19 12:45 EST
Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21
ENTAEnanta Pharmaceuticals2026-05-04 11:00 EST
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
AVIRAtea2026-01-06 12:00 EST
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
AVIRAtea2025-11-19 12:00 EST
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
Spero Therapeutics
Spero Therapeutics is an anti-infective company focused on bacterial infections and novel antibiotics. Its story is centered on addressing drug-resistant pathogens and difficult infection settings.
Recent company news
SPROSpero Therapeutics2026-07-27 13:00 EST
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
SPROSpero Therapeutics2026-07-14 11:02 EST
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
SPROSpero Therapeutics2026-05-13 16:05 EST
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
SPROSpero Therapeutics2026-05-05 16:05 EST
Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
SPROSpero Therapeutics2026-03-26 16:05 EST
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
Stock data
- Close
- 1.18 USD
- Market cap
- 163.86M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States